Company intelligence / Profile preview

Cordex Biologics

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Cordex Biologics, a subsidiary of ExCellThera, has developed UM171 Cell Therapy (INN: dorocubicel), an orphan-designated, allogeneic cord blood-derived CD34+ cell therapy evaluated in 120+ patients with hematological malignancies. Phase 2 trials demonstrated strong safety and efficacy signals in high-risk acute leukemia and myelodysplasia; an EMA-accelerated Phase 3 trial is planned for late 2024. The therapy has received Orphan Drug, RMAT, PRIME, and ATMP designations from major regulators[5][6][9][11].

Therapeutic areas: HematologyOncology
Modalities: Cell therapy
Industry: Biotech

Partnerships

ExCellThera

Beyond the preview

Go deeper on Cordex Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cordex Biologics.

Explore the full profile